The H1 2026 Oncology Landscape
The Oncology H1 2026 Landscape Review Series provides a comprehensive analysis of the trends, assets and companies shaping the future of cancer drug development. Built using data from Beacon as of July 2026, the series delivers a data-driven view of the evolving Oncology landscape across drug development, clinical trials, commercial activity and regulatory progress.
Across the series, you’ll uncover the modalities driving pipeline growth, the targets and indications attracting the greatest development activity, and the companies and technologies shaping investment, partnering and innovation trends. You’ll also gain visibility into emerging clinical activity, regulatory milestones, upcoming trial readouts and the assets expected to influence the next generation of Oncology therapies.
Start with Part 1: The Drug Development Landscape to benchmark the Oncology pipeline, identify areas of accelerating innovation and track the targets, modalities and disease areas attracting the greatest momentum.
Report Contents
The Drug Landscape
The Oncology pipeline surpassed 30,500 assets in H1 2026. Explore the therapeutic modalities driving growth, the most active cancer indications, and the trends shaping an increasingly diverse preclinical and clinical development landscape.
The Trial Landscape
Clinical trial activity continued to accelerate, with registrations on track for an estimated 24% year-over-year increase. Discover the most investigated targets, the leading clinical indications, and where activity is concentrated.
The Commercial Landscape
A deep dive into H1 2026 oncology market trends, including deal activity across Oncology drug targets, high-value licensing and collaboration agreements, active company hubs, and newly founded biopharma innovators.
Regulatory Announcements
Review the regulatory momentum of H1 2026, including a breakdown of IND/CTA approvals, major regulatory milestones, the top drugs by regulatory activity, and recently approved oncology therapies
The Innovation Landscape
Explore the most active Oncology drug targets, including CD19, BCMA, CD3, HER2 and PD-1. Discover where innovation is concentrated and how developers are pursuing both validated and emerging biology.
Future of the Oncology Landscape
An overview of the upcoming clinical trial landscape, and the Oncology assets to watch in 2026, including anticipated trial readouts, emerging therapeutic approaches and the most clinically active non-approved assets.
You May Also Be Interested In…
Learn More About Oncology
- The Most Comprehensive Way to Search the Oncology Drug Development Landscape: Unique search ontologies based on Oncology drug and trial characteristics
- Market Leading Approach to Oncology Preclinical & Clinical Data Curation: Manual curation of key Oncology research and development data points by Oncology research scientists
- Seamlessly Integrate Commercial & Scientific Data all in One Place: Search Oncology company and deal data based on their pipeline and technologies.
- Unrivalled Granularity in Reports & Analysis: Our search ontology and technology indexing enable comprehensive analysis not seen elsewhere.
What is Beacon?
Beacon is the essential intelligence platform for R&D decision-makers working in pharma and biotech, offering unique technology and drug datasets for complex therapeutics and disease areas.
Our market-defining proprietary ontologies, manual data curation, and accurate and comprehensive life science data, provide our customers with unparalleled visibility of the drug, trial and commercial landscape.
This is why 24 of the top 25 pharmaceutical companies trust Beacon to power their critical pipeline, competitive, and commercial decisions.
We’d welcome the opportunity to show you how Beacon can transform your data strategy. Book your personalized demonstration today!
